Pharvaris (NASDAQ:PHVS) Hits New 12-Month High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) shares reached a new 52-week high on Thursday . The company traded as high as $33.33 and last traded at $32.94, with a volume of 231127 shares. The stock had previously closed at $31.25.

Analyst Upgrades and Downgrades

PHVS has been the topic of several research reports. Citizens Jmp dropped their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Royal Bank Of Canada dropped their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Finally, Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Price Performance

The company has a market cap of $1.99 billion, a P/E ratio of -9.56 and a beta of -2.34. The company has a fifty day simple moving average of $28.14 and a 200-day simple moving average of $26.56.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, analysts anticipate that Pharvaris N.V. will post -3.35 EPS for the current year.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40. Following the sale, the director directly owned 355,167 shares of the company’s stock, valued at $10,768,663.44. The trade was a 7.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peng Lu sold 15,000 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the sale, the insider directly owned 66,083 shares in the company, valued at approximately $1,998,349.92. This trade represents a 18.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 150,659 shares of company stock valued at $4,489,587 in the last three months. 11.84% of the stock is currently owned by company insiders.

Institutional Trading of Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. GF Fund Management CO. LTD. acquired a new stake in Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris during the 3rd quarter valued at $75,000. Barclays PLC acquired a new stake in Pharvaris during the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris during the 4th quarter valued at $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.